Lewes, DE

Delaware Arthritis

Rheumatoid Arthritis

Arthritis

Osteoarthritis

Knee Osteoarthritis

Chronic Pain

Hip Osteoarthritis

Polymyalgia Rheumatica

Giant Cell Arteritis

Baricitinib

ABBV-154

Methotrexate

Adalimumab

Upadacitinib

ABT-494

Tanezumab

Olokizumab

AbbVie

Lilly

Pfizer

Crescendo Bioscience

R-Pharm

Sequenom

SetPoint Medical

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Delaware Arthritis | Lewes, DE

Site insights

Work at this site?

Active trials

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis (RESET-RA)

Trial sponsors